The technology we participate to develop, called "Zinc-Finger Artificial Transcription Factors (ZF-ATFs)", allows to design, realize and select artificial genes coding for proteins capable of recognizing and binding "potentially" any DNA sequence. We used ZF-ATF technology to reprogram the expression of "beneficial" genes capable of efficiently counteracting the negative effect of mutated genes related to rare diseases.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 15 of 18
Time-correlated single photon counting (TCSPC) is regarded as the “gold-standard” method for fluorescence lifetime measurements. However, TCSPC requires using highly sensitive detectors, not suitable for measurements under bright light conditions, thereby making the use impractical in clinical settings. The invention described here solves this problem by synchronizing the fluorescence detection with an external light source.
The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.
The present invention relates to a gamma camera for intracavitary use, which is widely used in the field of radio-guided surgery (intra-operative and laparoscopic and robotic-assisted) for the localisation of lymph nodes and tumours and/or other pathologies. The aim of the present invention is to make available an intraoperative tool able to overcome the drawbacks of the present known art.
Silicon nanowires (SiNWs) are 1D structures with diameter ranging from few tens to hundreds of nanometers and length varying from few tens of nanometers to millimiters. SiNWs are fabricated in the labs of the IMM-CNR, Rome Unit, by using bottom-up technologies such as plasma enhanced chemical vapor deposition (PECVD) at low growth temperature ((≤350°C), allowing the use of plastic and glassy substrates. Their electrical properties can be tuned by controlling the p/n doping during the growth.
The platform HistoPlat implies the development and validation of a mathematical algorithm, potentially combinable with an image analysis software, that, through a multiparametric approach including the immunohistochemical analysis of both expression and localization of multiple markers, allows the histopathologist or oncologist to optimize the diagnosis and prognosis, and to predict the clinical response to therapies directed towards validated and/or innovative molecular targets, also taking into account the individual variability of each pati
The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.
Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.
Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.
The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).
An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
Severe asthma or chronic obstructive pulmonary disease (COPD) are nowadays associated with a poor response to corticosteroids which led to the use of high-dose with consequent improved onset of side effects. The use of nanotechnologies can represent an innovative approach for the effective treatment of both asthma and COPD. The development of new nano-formulations involving the use of nanomaterials and specifically tailored to be inhaled offers numerous advantages over conventional inhaled dosage forms.
Therapeutic strategies targeting cell cycle in cancer have in general failed in the clinic since the drugs have lacked the therapeutic index required to achieve a robust response against cancer cells with little or no cytotoxic effect on normal cells. NEK6 kinase, which is implicated in cell cycle control, has recently emerged as an attractive target for the development of novel anticancer drugs with enhanced therapeutic index.
With the advent of senolytic agents, capable of selectively removing senescent cells in “aged” tissues, the perception of age-associated diseases has changed from being an inevitable to a preventable phenomenon of human life. The present invention is part of this research topic with the identification of molecules with potential pro-apoptotic activity, specifically with senolytic activity. The computational approach adopted, is based on combining ligand-base and structure-based virtual screening.